We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Australia’s Therapeutic Goods Administration is proposing changes to its low-value turnover exemption scheme that could help some devicemakers save money while reducing red tape and making the process more user-friendly and transparent. Read More
Health Canada exceeded its review targets for device submissions during the 2015 first quarter, reviewing new Class II devices in an average of nine days, six days quicker than the 15-day goal, and completing Class IV device reviews in an average of 70 days versus a 75-day goal. Read More
Devicemakers doing business in the Czech Republic face a steeper regulatory burden than before, thanks to regulations that took effect April 1. The new law requires devicemakers, importers and distributors to archive product safety documentation for five years and subject products to regular validation testing. Read More
Manufacturers planning to participate in the Medical Device Single Audit Program should first study up on Australian and Brazilian regulations, an official at the first company to go through a MDSAP audit says. Read More
The China Food and Drug Administration is proposing to require medical devicemakers to file clinical trial record forms, as the agency strengthens its oversight of devices. Read More
Health Canada is proposing 52 changes to its list of recognized standards for medical devices, including the addition of 26 new standards and updates to nine others. Read More
GMP violations including failure to submit a premarket approval application for its denture liner and failure to register the device in 2015 prompted an FDA warning letter to Better Health Systems. Read More
The FDA issued a warning letter to Thermedx, a Solon, Ohio-based manufacturer of gynecological and urological fluid management systems, for failing to notify the agency of device upgrades and other GMP violations. Read More
The U.S. FDA plans to withdraw 30 draft guidance documents affecting medical devices issued between 1988 and 2011, because they are obsolete or no longer considered necessary. Read More
Devicemakers looking to market their products for use in children based on adult clinical trials should limit their use of that data to situations in which the course of the disease or condition and the device’s effects are “sufficiently similar” in both populations, the U.S. FDA says. Read More